Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0013911 (emaciation)
 1,059 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

FK506 is a potent immunosuppressive agent on experimental and clinical organ transplantation. We studied the the effect of this agent on segmental pancreas allograft in mongrel dogs. Graft survival was prolonged significantly with continuous administration of FK506, 0.3mg/kg/day intramuscular and 1.0mg/kg/day orally. However such symptoms as loss of appetite, nausea and extreme emaciation were observed and caused death. While bolus therapy of FK506 (3 days administration with the dose of 1.0mg/kg i.m. from 4 to 6 day postoperatively) showed the same immunosuppressive effect as continuous therapy and less side effect. Furthermore it was suggested that FK506 plasma levels were concerned with the appearance of side effect. In conclusion, the administration of FK506 with plasma level monitoring was thought to be useful on pancreas transplantation.
 ...
PMID:[The effect of FK506 on segmental pancreas allograft in mongrel dogs]. 137 26

The immunosuppressive effect of FK506 (FK) in comparison to cyclosporine A (CsA) on lung graft rejection was demonstrated using 24 mongrel dogs with left lung allotransplantation. The cytotoxic activity of peripheral blood mononuclear cells was evaluated using donor skin fibroblasts. In eight dogs not given immunosuppression, the grafted lungs lost aeration 5-10 days postoperatively, and histologic findings revealed grade II rejection and cytotoxic activity elevated to between 10.7 and 60.5%, being an average of 31.2% at an effector/target (E/T) ratio of 50. Of 12 dogs treated with FK, none demonstrated a cytotoxic activity of 10% or more at an E/T ratio of 50. Moreover, histologic examinations of the specimens obtained by open chest biopsy revealed no signs of rejection during the first 10 postoperative days of FK administration, except in one dog showing grade I rejection from the FK 0.05 mg/kg group. A dose study of the duration until the onset of graft rejection and the elevation of cytotoxic activity after the termination of FK administration revealed approximately 1-2 weeks in the FK 0.05 mg/kg group, 3-4 weeks in the 0.1 mg/kg group, and later in the 0.4 mg/kg and 2.0 mg/kg groups. However, severe body weight loss was seen in the 0.4 mg/kg and 2.0 mg/kg groups postoperatively, without recovery even after the termination of FK. In fact, two dogs died of pneumonia possibly derived from general emaciation. These results suggest the optimal concentration of FK in canine lung allo-transplantation to be 0.1 mg/kg intramuscularly.
 ...
PMID:Dose study of the immunosuppression of FK 506 in canine lung allo-transplantation. 768 16

The effect of combination therapy with FK506 (FK) and 15-deoxyspergualin (DSG) was investigated in a concordant xenotransplantation model in which hamster hearts were implanted into LEW rats. Forty xenograft procedures were carried out in this study. Recipients were divided into eight groups. Control Group received no therapy. Group A, B, and C were administered different dosages of FK; 0.75, 1.0 and 1.25 (mg/kg/day), respectively. In Group D and E, DSG at 10 and 20 mg/kg/day was administered after the transplantation. In Group F and G received combined administration of FK and DSG (Group F; FK 0.5 + DSG 10, Group G; FK 0.5 + DSG 5). Recipients were injected with immunosuppressive agent intraperitoneally from day 0 until cessation of heart beat. At the time of grafting, splenectomy was performed in all groups. FK treatment of the recipients did not lead to significant improvement in graft survival, 7.2 +/- 0.8 and 6.3 +/- 0.7 days, compared with 3.5 +/- 1.23 days in Control. DSG groups showed xenograft survival of 11.5 +/- 0.9 and 8.1 +/- 1.6 days, respectively. The combined therapy prolonged graft survival to 33.67 +/- 11.37 days in Group F, and to 47.3 +/- 11.02 days in Group G. Combined therapy produced complete suppression of antibody formation, but in FK 0.5 + DSG 10 mg/kg/ day treated group, there was abrupt elevation of anti-hamster antibody titer at the time of rejection. Only in combined therapy groups did recipients obtain long-term graft survival, but recipients receiving treatment with FK 0.5 + DSG 10 (mg/kg/day) suffered from severe emaciation, losing nearly 31% of their body weight. However, animals that received a low dose of DSG in combined therapy groups did not lose body weight over 8 weeks. Combination therapy with FK and DSG was shown to prolong graft survival time effectively, and FK 0.5 + DSG 5 (mg/kg/day) was an appropriate dose in xenotransplantation with minimal side effects.
 ...
PMID:[Experimental study of the effectiveness of immunosuppression therapy using FK506 and 15-deoxyspergualin in concordant xenotransplantation]. 921 81

Using a swine abdominal organ cluster transplantation model, we investigated the postoperative function and immunological reactions of a cluster graft and evaluated the immunosuppressive activity of FK506. The animals were divided into two groups. Group I (n = 6) served as controls, while in group II (n = 6) a daily dose of 0.1 mg/kg FK506 was given intramuscularly. Postoperative pancreatitis was the most important factor influencing the early outcome in both groups. In group I, the cause of late death was cachexia due to diabetes mellitus induced by pancreatic rejection. In group II, emaciation despite a well-functioning graft was the principal cause of late death. Histologically, in group I the grade of rejection in the pancreas was more severe than in the liver, and no sign of rejection was observed in group II. In conclusion, the pancreas suffered more severe rejection than the liver, and FK506 could significantly prevent cluster allograft rejection in this model.
 ...
PMID:Abdominal organ cluster transplantation in pigs and FK506. 1462 61